Duvelisib
Fatal and Serious Toxicities: Infections, Diarrhea or Colitis, Cutaneous Reactions, and Pneumonitis
Infections
- Fatal and/or serious infections occurred in 31% of COPIKTRAtreated patients. Monitor for signs and symptoms of infection. Withhold COPIKTRA if infection is suspected.
Diarrhea or Colitis
- Fatal and/or serious diarrhea or colitis occurred in 18% of COPIKTRA-treated patients. Monitor for the development of severe diarrhea or colitis. Withhold COPIKTRA.
Cutaneous Reactions
- Fatal and/or serious cutaneous reactions occurred in 5% of COPIKTRA-treated patients. Withhold COPIKTRA.
Pneumonitis
- Fatal and/or serious pneumonitis occurred in 5% of COPIKTRAtreated patients. Monitor for pulmonary symptoms and interstitial infiltrates. Withhold COPIKTRA
Patient counseling
REMS
Medical guidelines
Package inserts
Keywords: Copiktra
Updated: October 2018